Back to Search
Start Over
Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients
- Source :
- Scientific Reports
- Publication Year :
- 2016
- Publisher :
- Springer Science and Business Media LLC, 2016.
-
Abstract
- Currently, amrubicin is permitted for relapsed small-cell lung carcinoma (SCLC) only in Japan. The efficacy and adverse effects of amrubicin as reported by previous studies varied greatly. The inclusion criterion was a prospective study that was able to provide data for efficacy and safety by the AMR single agent regimen as second-line chemotherapy for a patient with SCLC. Binary data were meta-analyzed with the random-model generic inverse variance method. We included nine articles consisted of 803 patients. The pooled three-, six- and nine-month progression-free survival were 63% (95% CI 57–69%, I2 = 53%), 28% (95% CI 21–35%, I2 = 71%) and 10% (95% CI 6–14%, I2 = 41%), respectively. The pooled six-, 12- and 18-month overall survival were 69% (95% CI 61–78%, I2 = 83%), 36% (95% CI 28–44%, I2 = 80%) and 15% (95% CI 8–21%, I2 = 81%), respectively. Amrubicin seemed much more beneficial for Japanese patients. However, compared to the efficacy of topotecan presented in a previous meta-analysis, amrubicin may be a better treatment option than topotecan for both Japanese and Euro-American. Adverse effects by amrubicin were almost exclusively observed to be hematological. Notably, grade III/IV neutropenia incidence was 70% and febrile neutropenia incidence was 12%.
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
Lung Neoplasms
Neutropenia
Antineoplastic Agents
Gastroenterology
White People
Article
03 medical and health sciences
0302 clinical medicine
Asian People
Japan
Recurrence
Internal medicine
Humans
Medicine
Anthracyclines
Prospective cohort study
Survival analysis
Multidisciplinary
business.industry
Incidence (epidemiology)
medicine.disease
Small Cell Lung Carcinoma
Survival Analysis
Surgery
Regimen
Treatment Outcome
030104 developmental biology
030220 oncology & carcinogenesis
Topotecan
business
Amrubicin
Febrile neutropenia
medicine.drug
Subjects
Details
- ISSN :
- 20452322
- Volume :
- 6
- Database :
- OpenAIRE
- Journal :
- Scientific Reports
- Accession number :
- edsair.doi.dedup.....e1224de5824e423269fb695f15ec8ef0